Cargando…

Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis

INTRODUCTION: Whole brain radiotherapy (WBRT) has been the mainstay treatment of brain metastases (BM) in non-small cell lung cancer (NSCLC) patients for years. Temozolomide (TMZ) could penetrate the blood–brain barrier and some studies showed that TMZ plus MBRT may improve clinical effectiveness. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Hua, Zheng, Shu-Yue, Zhou, Tian, Cui, Hui-Juan, Hu, Kai-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004645/
https://www.ncbi.nlm.nih.gov/pubmed/32000358
http://dx.doi.org/10.1097/MD.0000000000018455
_version_ 1783494770020057088
author Duan, Hua
Zheng, Shu-Yue
Zhou, Tian
Cui, Hui-Juan
Hu, Kai-Wen
author_facet Duan, Hua
Zheng, Shu-Yue
Zhou, Tian
Cui, Hui-Juan
Hu, Kai-Wen
author_sort Duan, Hua
collection PubMed
description INTRODUCTION: Whole brain radiotherapy (WBRT) has been the mainstay treatment of brain metastases (BM) in non-small cell lung cancer (NSCLC) patients for years. Temozolomide (TMZ) could penetrate the blood–brain barrier and some studies showed that TMZ plus MBRT may improve clinical effectiveness. This meta-analysis is aim to evaluate the clinical effectiveness and safety of TMZ plus MBRT in the NSCLC patients with BM. METHODS AND ANALYSIS: We systematically searched databases including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and four Chinese databases (Chinese Biomedical Database, China National Knowledge Infrastructure, Wanfang Database and Chinese Scientific Journal Database) without language restrictions from inception until July 26, 2019. Randomized controlled trials (RCTs) which compared TMZ plus WBRT with single WBRT in the advanced NSCLC patients with BM were included. The outcomes analysis reported objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), quality of life (QOL), and adverse effects. Two reviewers will independently extract data from the selected studies and assess the quality of studies. Statistical analyses will be performed using Review manager 5.3 software. Random-effects or fixed models were used to estimate pooled hazard ratio and relative risk. RESULTS: This systemic review and meta-analysis will evaluate the effects of TMZ plus MBRT in the NSCLC patients with BM in RCTs. CONCLUSION: Our study will provide evidence to judge if TMZ plus MBRT are effective treatment for NSCLC patients with BM.
format Online
Article
Text
id pubmed-7004645
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-70046452020-02-18 Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis Duan, Hua Zheng, Shu-Yue Zhou, Tian Cui, Hui-Juan Hu, Kai-Wen Medicine (Baltimore) 5700 INTRODUCTION: Whole brain radiotherapy (WBRT) has been the mainstay treatment of brain metastases (BM) in non-small cell lung cancer (NSCLC) patients for years. Temozolomide (TMZ) could penetrate the blood–brain barrier and some studies showed that TMZ plus MBRT may improve clinical effectiveness. This meta-analysis is aim to evaluate the clinical effectiveness and safety of TMZ plus MBRT in the NSCLC patients with BM. METHODS AND ANALYSIS: We systematically searched databases including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and four Chinese databases (Chinese Biomedical Database, China National Knowledge Infrastructure, Wanfang Database and Chinese Scientific Journal Database) without language restrictions from inception until July 26, 2019. Randomized controlled trials (RCTs) which compared TMZ plus WBRT with single WBRT in the advanced NSCLC patients with BM were included. The outcomes analysis reported objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), quality of life (QOL), and adverse effects. Two reviewers will independently extract data from the selected studies and assess the quality of studies. Statistical analyses will be performed using Review manager 5.3 software. Random-effects or fixed models were used to estimate pooled hazard ratio and relative risk. RESULTS: This systemic review and meta-analysis will evaluate the effects of TMZ plus MBRT in the NSCLC patients with BM in RCTs. CONCLUSION: Our study will provide evidence to judge if TMZ plus MBRT are effective treatment for NSCLC patients with BM. Wolters Kluwer Health 2020-01-31 /pmc/articles/PMC7004645/ /pubmed/32000358 http://dx.doi.org/10.1097/MD.0000000000018455 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Duan, Hua
Zheng, Shu-Yue
Zhou, Tian
Cui, Hui-Juan
Hu, Kai-Wen
Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis
title Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis
title_full Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis
title_fullStr Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis
title_full_unstemmed Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis
title_short Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis
title_sort temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: a protocol of an updated systematic review and meta-analysis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004645/
https://www.ncbi.nlm.nih.gov/pubmed/32000358
http://dx.doi.org/10.1097/MD.0000000000018455
work_keys_str_mv AT duanhua temozolomidepluswholebrainradiotherapyforthetreatmentofnonsmallcelllungcancerpatientswithbrainmetastasesaprotocolofanupdatedsystematicreviewandmetaanalysis
AT zhengshuyue temozolomidepluswholebrainradiotherapyforthetreatmentofnonsmallcelllungcancerpatientswithbrainmetastasesaprotocolofanupdatedsystematicreviewandmetaanalysis
AT zhoutian temozolomidepluswholebrainradiotherapyforthetreatmentofnonsmallcelllungcancerpatientswithbrainmetastasesaprotocolofanupdatedsystematicreviewandmetaanalysis
AT cuihuijuan temozolomidepluswholebrainradiotherapyforthetreatmentofnonsmallcelllungcancerpatientswithbrainmetastasesaprotocolofanupdatedsystematicreviewandmetaanalysis
AT hukaiwen temozolomidepluswholebrainradiotherapyforthetreatmentofnonsmallcelllungcancerpatientswithbrainmetastasesaprotocolofanupdatedsystematicreviewandmetaanalysis